四君子汤合沙参麦冬汤加减联合IMRT放疗治疗局部复发食管鳞癌的疗效和安全性

目的:初步探讨四君子汤合沙参麦冬汤加减联合IMRT放疗治疗局部复发食管鳞癌的有效性和安全性。方法:43例食管癌患者随机分为2组，试验组22例，在IMRT放疗的基础上联用四君子汤合沙参麦冬汤加减，水煎服，每日一剂，早晚服用，于放疗第1天开始，放疗结束两周后停用；对照组21例只行IMRT放疗。结果:试验组与对照组的近期有效率（RR）和疾病控制率（DCR）分别为59.1%、86.4%和42.9%、61.9%，差异无统计学意义(P>0.05）；1、2、3年生存率虽然治疗组较对照组确有提高，但差异无统计学意义(P>0.05）；试验组白细胞减少、血小板减少、血红蛋白减少、放射性肺炎均较对照组发生率明显降低，差异有统计学意义（P<0.05)。结论:四君子汤合沙参麦冬汤加减联合IMRT放疗治疗局部复发食管鳞癌患者可以明显降低放疗所致不良反应，一定程度改善患者的治疗效果和1、2、3年生存率。

Efficacy and safety of modified sijunzi decoction plus shashen maidong decoction concurrent with IMRT in patients with local-recurrence esophageal squamous carcinoma

Objective:To evaluate the efficacy and safety of modified sijunzi decoction plus shashen maidong decoction concurrent with intensity-modulated radiotherapy(IMRT) for patients with local-recurrence esophageal squamous carcinoma.Methods:For forty-three patients were randomly divided into the trial group(22 patients) and the control group(21 patients).Twenty-two patients of the trial group received modified sijunzi decoction plus shashen maidong decoction concurrent with IMRT.Twenty-one patients of the control group received IMRT only.Results:The resent response rate(RR) and the disease control rate(DCR) of the trial group and control group were 59.1%，86.4% and 42.9%，61.9%，respectively(P>0.05).The 1-，2-，3-survival rate of the trial group was elevated to some degree compared to the control group，but the difference was not statistically significant(P>0.05).The trail group of leukopenia，thrombocytopenia，decreased hemoglobin，and radiation pneumonitis was reduced obvious compared to control group(P<0.05).Conclusion:Modified sijunzi decoction plus shashen maidong decoction concurrent with IMRT could decrease the adverse effects of the radiotherapy obviously in the patients with local-recurrence esophageal squamous carcinoma，improved the therapeutic effect and the 1-，2-，3-survival rate to some degree.